14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 29.013 Session: Malaria & Blood-borne Parasites Date: Wednesday, March 10, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Cardiac function and haemodynamics in African children with severe malaria S. Yacoub 1 , H.-J. Lang 2 , M. shebbe 3 , M. Twimba 3 , E. Ohuma 3 , R. Tulloh 4 , K. Maitland 3 1 Imperial College, W12 0NN, United Kingdom, 2 Imperial college, London, United Kingdom, 3 Kenya Medical Research Institute- Wellcome Trust Programme, Kilifi, Kenya, 4 Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom Background: Mortality from severe malaria remains unacceptably high in sub-Saharan Africa. Several markers of cardiovascular compromise and metabolic acidosis correlate with mortality. The role of cardiac dysfunction in the pathogenesis of severe childhood malaria remains unknown. In this study we aimed to investigate cardiac function and haemodynamic status of children admitted with severe malaria, assessing changes over time and response to fluid resuscitation. Methods: Setting:High Dependency Unit, Kilifi District Hospital, Kenya. We examined thirty children admitted with severe malaria using portable echocardiography to assess their cardiac function and haemodynamic status on admission (day 0), day 1, and discharge. We compared haemodynamic parameters in two study groups: children presenting with metabolic acidosis (base deficit > 8) and children without acidosis. Acidotic patients received fluid resuscitation with either Dextran 70 or Hetastarch at admission. Results: Several markers of haemodynamic compromise were noted on admission including severe tachycardia, low stroke volume index (SVI) and high inferior vena cava collapsibility index (IVCCI) that improved with subsequent readings (fig 1). Overall, cardiac function assessed by ejection fraction (63.1% ± 5.2 vs. 71.9% ± 2.8 P=
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 29.014 Session: Malaria & Blood-borne Parasites Date: Wednesday, March 10, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Transfusion-associated Babesia infections: Reports received by the FDA 1997 to 2008 D. Gubernot, K. C. Lee, G. B. Conley, L. G. Holness, S. O'Callaghan, S. Cannon, E. Cowan, H. Nakhasi, R. P. Wise Food and Drug Administration, Rockville, MD, USA Background: Babesiosis is a known transfusion-transmitted disease risk and there is no FDAlicensed test for donor screening. Approximately 80 transfusion-transmitted cases have been reported 1979 through 2008. This research evaluated the Babesia-related transfusion events reported to the Food and Drug Administration (FDA) with particular focus on numbers and characteristics of transfusion-related babesiosis fatality reports. Methods: Data were collected from FDA's Blood Collection and Transfusion Fatality Reporting and Biological Product Deviation Reports (BPDRs) surveillance systems. Results: From 2005 through 2008, the FDA received 10 transfusion-related babesiosis fatality reports after only one prior report in 1998. Recipients presented with symptoms 2.5 to 9 weeks after transfusion of implicated red blood cell units. In recent years, FDA has also seen an increase in Babesia-related BPDRs involving donors with post donation illness and reports of potential transfusion-transmitted disease. Most reports submitted to the FDA implicate B. microti. Conclusion: The reports received by the FDA indicate Babesia infection may be a rare but increasing risk to the blood supply. Without a licensed screening test to prevent these transmissions, enhanced clinician awareness of the possibility of babesiosis in febrile, recent transfusion recipients may facilitate prompt diagnosis, improved prognosis, and more timely investigations to interdict infected units. Prompt reporting of babesiosis donor and transfusionrelated events assists the FDA in assessing the scope of this risk and developing appropriate public health control measures. Disclaimer: The findings and conclusions in this abstract have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130: When citing these abstracts please
Page 179: When citing these abstracts please
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?